Abstract:As a member of cyclic nucleotide phosphodiesterase (PDE) enzyme family, PDE10A is in charge of the degradation of cyclic adenosine (cAMP) and guanosine monophosphates (cGMP). While PDE10A is primarily expressed in the medium spiny neurons of the striatum, it has been implicated in a variety of neurological disorders. Indeed, inhibition of PDE10A has proven to be of potential use for the treatment of central nervous system (CNS) pathologies caused by dysfunction of the basal ganglia-of which the striatum constitutes the largest component. A PDE10A-targeted positron emission tomography (PET) radioligand would enable a better assessment of the pathophysiologic role of PDE10A, as well as confirm the relationship between target occupancy and administrated dose of a given drug candidate, thus accelerating the development of effective PDE10A inhibitors. In this study, we designed and synthesized a novel 18F-aryl PDE10A PET radioligand, codenamed [18F]P10A-1910 ([18F]9), in high radiochemical yield and molar ac-tivity via spirocyclic iodonium ylide-mediated radiofluorination. [18F]9 possessed good in vitro binding af-finity (IC50 = 2.1 nmol/L) and selectivity towards PDE10A. Further, [18F]9 exhibited reasonable lipophilicity (logD = 3.50) and brain permeability (Papp > 10 x 10-6 cm/s in MDCK-MDR1 cells). PET imaging studies of [18F]9 revealed high striatal uptake and excellent in vivo specificity with reversible tracer kinetics. Preclinical studies in rodents revealed an improved plasma and brain stability of [18F]9 when compared to the current reference standard for PDE10A-targeted PET, [18F]MNI659. Further, dose-response experiments with a series of escalating doses of PDE10A inhibitor 1 in rhesus monkey brains confirmed the utility of [18F]9 for evaluating target occupancy in vivo in higher species. In conclusion, our results indicated that [18F]9 is a promising PDE10A PET radioligand for clinical translation. 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sci-ences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Discovery of 3-Trifluoromethyl-substituted Pyrazoles As Selective Phosphodiesterase 10A Inhibitors for Orally Attenuating Isoprenaline-Induced Cardiac Hypertrophy

Discovery of Herbacetin As a Novel SGK1 Inhibitor to Alleviate Myocardial Hypertrophy

Validation of Phosphodiesterase-10 As a Novel Target for Pulmonary Arterial Hypertension Via Highly Selective and Subnanomolar Inhibitors.

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension

Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.

Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones As Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.

C33(S), A Novel Pde9a Inhibitor, Protects Against Rat Cardiac Hypertrophy Through Upregulating Cgmp Signaling

Discovery and Optimization of Dihydroquinolin-2(1 H )-ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Discovery of Novel Pyrazolo[3,4- b ] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension

Discovery of Pyridazinone Derivatives Bearing Tetrahydroimidazo[1,2-A]pyrazine Scaffold As Potent Inhibitors of Transient Receptor Potential Canonical 5 to Ameliorate Hypertension-Induced Renal Injury in Rats

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway

Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket

Discovery of a Highly Specific 18F-Labeled PET Ligand for Phosphodiesterase 10A Enabled by Novel Spirocyclic Iodonium Ylide Radiofluorination.

CPUY11018, an azimilide derivative, ameliorates isoproterenol-induced cardiac insufficiency through relieving dysfunctional mitochondria and endoplasmic reticulum.

Design, synthesis and optimization of pyrazolo[3,4-b] pyridine derivatives as Hsp110-STAT3 interaction disruptors for the treatment of pulmonary arterial hypertension

Design and synthesis of 3,4- seco -lupane triterpene derivatives to resist myocardial ischemia-reperfusion injury by inhibiting oxidative stress-mediated mitochondrial dysfunction via the PI3K/AKT/HIF-1α axis

Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway

Discovery of [11C]MK-8193 As a PET Tracer to Measure Target Engagement of Phosphodiesterase 10A (PDE10A) Inhibitors